#For patients
Written for adults considering a peptide as part of their health management.
Semaglutide and Bipolar Disorder: The Data
A Swedish national cohort links semaglutide, not other GLP-1 drugs, to fewer bipolar hospitalizations. Here is what the data shows and does not yet show.
Tirzepatide, Dulaglutide: Patient Voices
Exit interviews from the SURPASS-CVOT trial capture what patients on tirzepatide and dulaglutide said helped, and what did not.
Tesamorelin under 1mg: what the data says
Egrifta's labeled tesamorelin dose is 1.28 mg daily, and no trial has published data below 1 mg or tested it against sermorelin.
Tirzepatide and eyelid styes: what's known
A two-patient case series reports recurring eyelid styes and chalazia after tirzepatide, with one positive rechallenge.
GLP-1 Drugs and Lumbar Fusion Surgery
A new meta-analysis found no significant link between GLP-1 drugs like semaglutide and complications after lumbar fusion surgery.
GLP-1 Drugs in Teens: The Nutrition Gap
A pediatric claims study finds nutritional deficiencies in teens on semaglutide and similar GLP-1 drugs, with most never referred for nutrition counseling.
GLP-1 and PCOS: Reading a New Letter
A 2026 letter raises a possible GLP-1 and PCOS association, but genetic and reporting evidence cannot establish cause or guide treatment.
Semaglutide, weight loss and body image
Semaglutide trials measure weight and health outcomes. They cannot promise confidence, happiness, or a particular body-image result.
GLP-1 Patient Experiences in Jeddah
A survey in three Jeddah hospitals recorded patient concerns about GLP-1 medicines, but its cross-sectional design cannot establish causation.
Oral Semaglutide: A 25-Person Readout
A 25-person Japanese study linked oral semaglutide with lower energy intake, weight and body fat after three months, with key muscle caveats.
Facial nodules and compounded tirzepatide
One case linked facial nodules to compounded tirzepatide, but missing biopsy and cultures leave inflammation, infection and product factors unresolved.
What a tirzepatide COA cannot verify
A COA may describe a tested sample, but it cannot replace FDA approval, licensed pharmacy dispensing, or individual clinical assessment.